An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
written informed consent provided prior to participation in the extension study.
successful completion of the study CLIC477D2302
willingness and ability to comply with all study requirements
You may not be if
premature discontinuation from the study CLIC477D2302
failure to comply with the study CLIC477D2302 protocol
Clareo Health | An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder
